Physician profile
Steven Kim
NPI 1659040574
$11,847.05
in general payments reported to CMS, 2019-2025
27 companies · $3,615 in 2025
The $3,615 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.21 · 2022: $2,026 · 2023: $3,159 · 2024: $2,968 · 2025: $3,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,631 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,630.76 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,560.60 | 2022-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,085.25 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,020.72 | 2021-2025 | Ingrezza |
| Abbvie INC. | $950.74 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $826.68 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $749.46 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $663.33 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $656.07 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $651.66 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $646.10 | 2022-2025 | Fanapt, Hetlioz |
| Corium, LLC | $641.44 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $595.40 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $357.52 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $301.58 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $257.41 | 2021-2023 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $180.98 | 2022-2025 | Onyda Xr |
| Indivior INC. | $180.86 | 2022-2024 | Perseris |
| Tempus Ai, INC | $177.56 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Sunovion Pharmaceuticals INC. | $111.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.17 | 2023 | Belsomra |
| Neos Therapeutics, LP | $48.96 | 2022-2023 | Adzenys Xr-Odt |
| Medtronic, INC. | $38.48 | 2022 | |
| Angiodynamics, INC. | $28.75 | 2025 | Alphavac |
| Sage Therapeutics, LLC | $23.75 | 2024 | |
| Vertical Pharmaceuticals, LLC | $15.42 | 2025 | Relexxii |
| Neuronetics, INC. | $14.70 | 2023 | Neurostar Tms Therapy System |
| Eisai INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.